MA42527A - Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation - Google Patents

Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Info

Publication number
MA42527A
MA42527A MA042527A MA42527A MA42527A MA 42527 A MA42527 A MA 42527A MA 042527 A MA042527 A MA 042527A MA 42527 A MA42527 A MA 42527A MA 42527 A MA42527 A MA 42527A
Authority
MA
Morocco
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
MA042527A
Other languages
English (en)
French (fr)
Inventor
Konrad Feichtinger
Juerg Lehmann
Albert S Ren
Graeme Semple
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA42527A publication Critical patent/MA42527A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MA042527A 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation MA42527A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
MA42527A true MA42527A (fr) 2021-04-07

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042527A MA42527A (fr) 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Country Status (14)

Country Link
US (4) US10272094B2 (OSRAM)
EP (1) EP3328835B1 (OSRAM)
JP (1) JP6789578B2 (OSRAM)
KR (1) KR20180031035A (OSRAM)
CN (1) CN108137508B (OSRAM)
AU (1) AU2016302755B2 (OSRAM)
BR (1) BR112018001707A2 (OSRAM)
CA (1) CA3002525A1 (OSRAM)
EA (1) EA039412B1 (OSRAM)
HK (1) HK1255850A1 (OSRAM)
IL (1) IL257107B (OSRAM)
MA (1) MA42527A (OSRAM)
MX (1) MX375045B (OSRAM)
WO (1) WO2017023679A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6789578B2 (ja) * 2015-07-31 2020-11-25 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
EP4363287A2 (en) * 2021-06-29 2024-05-08 Tusimple, Inc. Systems and methods for operating an autonomous vehicle
US12227206B2 (en) 2021-10-14 2025-02-18 Tusimple, Inc. Systems and methods for operating an autonomous vehicle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
JP4782003B2 (ja) * 2003-06-17 2011-09-28 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
US20120253036A1 (en) * 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
HK1212684A1 (zh) * 2012-09-14 2016-06-17 AbbVie Deutschland GmbH & Co. KG 三環喹啉和喹喔啉衍生物
JP6789578B2 (ja) 2015-07-31 2020-11-25 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法

Also Published As

Publication number Publication date
JP6789578B2 (ja) 2020-11-25
MX2018001380A (es) 2018-06-15
BR112018001707A2 (pt) 2018-09-18
JP2018522025A (ja) 2018-08-09
CN108137508A (zh) 2018-06-08
AU2016302755A1 (en) 2018-03-15
EP3328835A1 (en) 2018-06-06
MX375045B (es) 2025-03-06
IL257107B (en) 2021-03-25
EA039412B1 (ru) 2022-01-25
NZ739883A (en) 2021-03-26
US20200383993A1 (en) 2020-12-10
KR20180031035A (ko) 2018-03-27
US20180214455A1 (en) 2018-08-02
HK1255850A1 (zh) 2019-08-30
AU2016302755B2 (en) 2020-09-10
CN108137508B (zh) 2021-08-27
US10272094B2 (en) 2019-04-30
US11395824B2 (en) 2022-07-26
EA201890402A1 (ru) 2018-09-28
EP3328835B1 (en) 2022-10-12
US20230055376A1 (en) 2023-02-23
IL257107A (en) 2018-03-29
CA3002525A1 (en) 2017-02-09
US20200078368A1 (en) 2020-03-12
WO2017023679A1 (en) 2017-02-09
US10624900B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
EP3359523A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
EP3325017A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
EP3352774A4 (en) FLAVONOID COMPOSITIONS AND METHODS OF USE
MA41613A (fr) Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
EP3373906A4 (en) COMPOSITIONS AND METHOD OF APPLICATION TO THE SKIN
EP3380101A4 (en) EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
IL255171A0 (en) 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3414321A4 (en) VCN CONVEYOR COMPOSITIONS AND METHOD FOR USE THEREOF
EP3394065A4 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF
EP3303435A4 (en) HYDROFLUOROLEFINES AND METHOD OF USE THEREOF
EP3621660A4 (en) COMPOSITIONS AND METHODS OF USING ARC-CAPSIDES
EP3386927A4 (en) POLYMERIC COMPOSITIONS AND METHODS OF USE
EP3316894A4 (en) COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
EP3384274A4 (en) DEVICES AND METHOD FOR SAMPLE CHARACTERIZATION
EP3310383A4 (en) COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION
EP3478277A4 (en) ANTI-ACNE COMPOSITIONS AND METHOD FOR USE
EP3289064A4 (en) COMPOSITIONS AND METHODS FOR DETECTING ALLERGENS
EP3302558A4 (en) ANTI-TUMOR MEDIUM AND METHOD OF USE
IL264682B (en) 5-HT2C receptor agonists and preparations and methods of use
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3373950A4 (en) METHOD AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICATIONS
EP3364984A4 (en) COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF